États-Unis · Plateformes & données · Briefing.com

Vaxcyte Surges as OPUS-1 Phase 3 Results Strengthen VAX-31 Regulatory Path (PCVX)

Publié par Briefing.com · États-Unis il y a 14 j

Vaxcyte (PCVX) is soaring today after announcing topline results from the pivotal Phase 3 OPUS-1 trial evaluating VAX-31. VAX-31 is PCVX's investigational 31-valent pneumococcal…

Lire l'article complet sur Briefing.com Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.briefing.com)

Vaxcyte Surges as OPUS-1 Phase 3 Results Strengthen VAX-31 Regulatory Path (PCVX)

À lire aussi

eToro Group (NASDAQ:ETOR) Sets New 52-Week Low on Analyst Downgrade

Better Retail Stock for 2026: GameStop vs. MercadoLibre

Cleveland-Cliffs projects $715M Q4 adjusted EBITDA and outlines path to more than $4B in 2027

One of this year’s most important relationships in global financial markets is falling apart

Anthropic is AI trade's last big hope for a major IPO this year

Cadence Design Systems stock may move 6.2% on earnings

Vaxcyte Surges as OPUS-1 Phase 3 Results Strengthen VAX-31 Regulatory Path (PCVX)

Partager

À lire aussi

eToro Group (NASDAQ:ETOR) Sets New 52-Week Low on Analyst Downgrade

Better Retail Stock for 2026: GameStop vs. MercadoLibre

Cleveland-Cliffs projects $715M Q4 adjusted EBITDA and outlines path to more than $4B in 2027

One of this year’s most important relationships in global financial markets is falling apart

Anthropic is AI trade's last big hope for a major IPO this year

Cadence Design Systems stock may move 6.2% on earnings